Jan 23 (Reuters) – Bausch Health said on Friday its treatment to prevent brain dysfunction in patients with liver cirrhosis did not meet the main goal of two late-stage trials. The studies tested a new version of its antibiotic rifaximin to prevent hepatic encephalopathy, a condition where the liver can not remove toxins from the […]
Health
Bausch Health’s brain dysfunction treatment fails late-stage trials
Audio By Carbonatix
Jan 23 (Reuters) – Bausch Health said on Friday its treatment to prevent brain dysfunction in patients with liver cirrhosis did not meet the main goal of two late-stage trials.
The studies tested a new version of its antibiotic rifaximin to prevent hepatic encephalopathy, a condition where the liver can not remove toxins from the blood, allowing them to build up and impair brain function, causing confusion and potentially coma.
“We are disappointed in the results, as there is currently no approved treatment for these patients,” CEO Thomas Appio said, adding that the company is reviewing the data for other potential development opportunities.
U.S.-listed shares of Bausch fell nearly 5% in premarket trading.
(Reporting by Christy Santhosh and Sahil Pandey in Bengaluru; Editing by Shilpi Majumdar)